Harnessing genetically engineered cell membrane-derived vesicles as biotherapeutics
2024

Harnessing Genetically Engineered Cell Membrane-Derived Vesicles as Biotherapeutics

publication 10 minutes Evidence: moderate

Author Information

Author(s): Li Xiaohong, Wei Yuting, Zhang Zhirang, Zhang Xudong

Primary Institution: Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Sun Yat-Sen University

Hypothesis

Can genetically engineered cell membrane-derived vesicles (CMVs) be effectively utilized as biotherapeutics for various diseases?

Conclusion

Genetically engineered CMVs show promise as a novel drug delivery system for treating cancer, diabetes, and other diseases.

Supporting Evidence

  • CMVs have stable lipid bilayer structures and favorable biocompatibility.
  • Genetic engineering can enhance the targeting and therapeutic effects of CMVs.
  • Engineered CMVs can deliver drugs and nucleic acids effectively.
  • CMVs can be used in treating tumors, diabetes, and autoimmune diseases.

Takeaway

Scientists are using tiny bubbles made from cell membranes to deliver medicine directly to sick cells, which could help treat diseases like cancer and diabetes.

Methodology

The review outlines preparation strategies, characteristics for purifying CMVs, and advances in their use for targeting organs and delivering drugs.

Limitations

Genetically modified CMVs may have issues with packing efficiency and potential damage to donor cell activity.

Digital Object Identifier (DOI)

10.20517/evcna.2023.58

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication